Amundi Pioneer Asset Management Inc. lowered its stake in Agilent Technologies, Inc. (NYSE:A) by 16.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 2,343,313 shares of the medical research company’s stock after selling 472,164 shares during the quarter. Amundi Pioneer Asset Management Inc. owned approximately 0.77% of Agilent Technologies worth $277,644,000 as of its most recent SEC filing.
Several other large investors also recently added to or reduced their stakes in A. Jacobi Capital Management LLC increased its position in shares of Agilent Technologies by 80.0% in the fourth quarter. Jacobi Capital Management LLC now owns 225 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 100 shares during the last quarter. Fieldpoint Private Securities LLC acquired a new stake in shares of Agilent Technologies in the fourth quarter valued at about $31,000. Truehand Inc acquired a new position in Agilent Technologies during the fourth quarter worth approximately $33,000. Jackson Grant Investment Advisers Inc. acquired a new position in Agilent Technologies during the fourth quarter worth approximately $33,000. Finally, Your Advocates Ltd. LLP acquired a new position in Agilent Technologies during the fourth quarter worth approximately $35,000.
A number of equities analysts have weighed in on A shares. Mizuho started coverage on Agilent Technologies in a research report on Tuesday, January 12th. They set a “buy” rating and a $51.00 price target on the stock. SVB Leerink boosted their price target on Agilent Technologies from $130.00 to $140.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 17th. Redburn Partners upgraded Agilent Technologies from a “neutral” rating to a “buy” rating in a report on Friday, March 19th. KeyCorp boosted their price objective on Agilent Technologies from $130.00 to $148.00 in a report on Wednesday, February 17th. Finally, Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell upgraded Agilent Technologies from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $135.00 to $150.00 in a report on Wednesday, March 24th. Nine research analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $105.40.
Agilent Technologies (NYSE:A) last posted its quarterly earnings data on Monday, February 15th. The medical research company reported $1.06 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.89 by $0.17. The business had revenue of $1.55 billion during the quarter, compared to the consensus estimate of $1.43 billion. Agilent Technologies had a return on equity of 21.02% and a net margin of 13.47%. During the same period in the prior year, the business posted $0.81 earnings per share. Research analysts expect that Agilent Technologies, Inc. will post 3.67 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 28th. Investors of record on Tuesday, April 6th will be issued a $0.194 dividend. The ex-dividend date of this dividend is Monday, April 5th. This represents a $0.78 dividend on an annualized basis and a yield of 0.60%. Agilent Technologies’s payout ratio is 23.78%.
Agilent Technologies declared that its board has initiated a share buyback program on Tuesday, February 16th that authorizes the company to buyback $2.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to reacquire up to 5% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s board of directors believes its shares are undervalued.
In other Agilent Technologies news, VP Samraat S. Raha sold 1,000 shares of the company’s stock in a transaction on Wednesday, March 31st. The shares were sold at an average price of $127.50, for a total transaction of $127,500.00. Also, CEO Michael R. Mcmullen sold 21,212 shares of the company’s stock in a transaction on Monday, February 1st. The shares were sold at an average price of $120.26, for a total transaction of $2,550,955.12. Following the sale, the chief executive officer now directly owns 356,963 shares in the company, valued at approximately $42,928,370.38. The disclosure for this sale can be found here. Insiders have sold 22,712 shares of company stock worth $2,742,090 in the last ninety days.
Agilent Technologies Company Profile
Agilent Technologies, Inc engages in the provision of application focused solutions for life sciences, diagnostics and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that enable to identify, quantify and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level.
Further Reading: Understanding each part of a balance sheet
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.